Cargando…

The European Medicines Agency Review of Luspatercept for the Treatment of Adult Patients With Transfusion-dependent Anemia Caused by Low-risk Myelodysplastic Syndromes With Ring Sideroblasts or Beta-thalassemia

Luspatercept is a recombinant fusion protein that selectively binds to ligands belonging to the transforming growth factor-beta superfamily, resulting in erythroid maturation and differentiation. On June 25, 2020, a marketing authorization valid through the European Union (EU) was issued for luspate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Delgado, Julio, Voltz, Caroline, Stain, Milena, Balkowiec-Iskra, Ewa, Mueller, Brigitte, Wernsperger, Johanna, Malinowska, Iwona, Gisselbrecht, Christian, Enzmann, Harald, Pignatti, Francesco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2021
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8288896/ https://www.ncbi.nlm.nih.gov/pubmed/34291195 http://dx.doi.org/10.1097/HS9.0000000000000616

Ejemplares similares

Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblasts
por: Zeidan, Amer M., et al.
Publicado: (2022)

Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis
por: Komrokji, Rami S., et al.
Publicado: (2022)

The European Medicines Agency Review of Crizanlizumab for the Prevention of Recurrent Vaso-Occlusive Crises in Patients With Sickle Cell Disease
por: Delgado, Julio, et al.
Publicado: (2021)

Immune Complex Glomerulonephritis in a Patient with Myelodysplastic Syndrome with Ring Sideroblasts Treated with Luspatercept
por: Delanghe, Sigurd, et al.
Publicado: (2022)

Luspatercept‐induced reduction in transfusion requirement in α‐thalassemia
por: Jackson, Nicholas, et al.
Publicado: (2020)

Luspatercept: A New Tool for the Treatment of Anemia Related to β-Thalassemia, Myelodysplastic Syndromes and Primary Myelofibrosis
por: Hatzimichael, Eleftheria, et al.
Publicado: (2022)

Long-term utilization and benefit of luspatercept in transfusion-dependent, erythropoiesis-stimulating agent-refractory or -intolerant patients with lower-risk myelodysplastic syndromes with ring sideroblasts
por: Platzbecker, Uwe, et al.
Publicado: (2023)

Luspatercept for transfusion-dependent β-thalassemia: time to get real
por: Musallam, Khaled M., et al.
Publicado: (2023)

Health-Related Quality of Life Outcomes in Patients with Myelodysplastic Syndromes with Ring Sideroblasts Treated with Luspatercept in the MEDALIST Phase 3 Trial
por: Oliva, Esther Natalie, et al.
Publicado: (2021)

Megaloblastic Anemia with Ring Sideroblasts is not Always Myelodysplastic Syndrome
por: Narang, Neha Chopra, et al.
Publicado: (2016)

Activity of luspatercept and ESAs combination for treatment of anemia in lower-risk myelodysplastic syndromes
por: Komrokji, Rami S., et al.
Publicado: (2023)

Clinical and genetic characteristics of congenital sideroblastic anemia: comparison with myelodysplastic syndrome with ring sideroblast (MDS-RS)
por: Ohba, Rie, et al.
Publicado: (2012)

Profile of Luspatercept in the Treatment of Anemia in Adults with Non-Transfusion-Dependent β-Thalassemia (NTDT): Design, Development and Potential Place in Therapy
por: Musallam, Khaled M, et al.
Publicado: (2023)

Comment: In Response to “Megaloblastic Anemia with Ring Sideroblasts is not Always Myelodysplastic Syndrome”
por: Gajendra, Smeeta
Publicado: (2017)

P1506: REAL-WORLD DATA ON THE USE OF LUSPATERCEPT IN GREEK PATIENTS WITH TRANSFUSION DEPENDENT THALASSEMIA
por: Delaporta, P., et al.
Publicado: (2022)

Role of Luspatercept in the Management of Lower-Risk Myelodysplastic Syndromes
por: Tinsley-Vance, Sara M., et al.
Publicado: (2023)

Plasma proteome changes associated with refractory anemia and refractory anemia with ringed sideroblasts in patients with myelodysplastic syndrome
por: Májek, Pavel, et al.
Publicado: (2013)

Cardiac iron overload in chronically transfused patients with thalassemia, sickle cell anemia, or myelodysplastic syndrome
por: de Montalembert, Mariane, et al.
Publicado: (2017)

Efficacy and Safety of Luspatercept in the Treatment of β-Thalassemia: A Systematic Review
por: Dighriri, Ibrahim M, et al.
Publicado: (2022)

Treating Thalassemia Patients with Luspatercept: An Expert Opinion Based on Current Evidence
por: Longo, Filomena, et al.
Publicado: (2023)

Cardiac and hepatic siderosis in myelodysplastic syndrome, thalassemia and diverse causes of transfusion-dependent anemia: the TIMES study
por: Ho, P. Joy, et al.
Publicado: (2019)

Anemia with thrombocytosis in an elderly male: a case of myelodysplastic syndrome-myeloproliferative neoplasm with ringed sideroblasts and thrombocytosis
por: Kumar, Ashutosh, et al.
Publicado: (2018)

Gaucher-like cells in myelodysplastic syndrome with ring sideroblasts
por: El Khoury, Christelle, et al.
Publicado: (2022)

Myelodysplastic syndrome/myeloproliferative neoplasm with ringed sideroblasts and thrombocytosis
por: Tasleem, Azka, et al.
Publicado: (2021)

Luspatercept mitigates bone loss driven by myelodysplastic neoplasms and estrogen-deficiency in mice
por: Weidner, Heike, et al.
Publicado: (2022)

Long-term safety and erythroid response with luspatercept treatment in patients with β-thalassemia
por: Piga, Antonio, et al.
Publicado: (2022)

Severe isoniazid related sideroblastic anemia
por: Piso, Rein Jan, et al.
Publicado: (2011)

Refractory anemia with ring sideroblasts and thrombocytosis
por: Pradhan, Sarita
Publicado: (2017)

Causes and Pathophysiology of Acquired Sideroblastic Anemia
por: Rodriguez-Sevilla, Juan Jose, et al.
Publicado: (2022)

Recurrent sideroblastic anemia during pregnancy
por: Mohamed, Shehab, et al.
Publicado: (2023)

The European Medicines Agency Review of Tafasitamab in Combination With Lenalidomide for the Treatment of Adult Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
por: Delgado, Julio, et al.
Publicado: (2021)

Long-Term Efficacy and Safety of Luspatercept for Anemia Treatment in Patients With Lower-Risk Myelodysplastic Syndromes: The Phase II PACE-MDS Study
por: Platzbecker, Uwe, et al.
Publicado: (2022)

New developments in the understanding and diagnosis of myelodysplastic syndromes with ring sideroblasts()
por: Ribeiro, Lorena Bedotti, et al.
Publicado: (2016)

Prognostic impact of gene mutations in myelodysplastic syndromes with ring sideroblasts
por: Martín, Iván, et al.
Publicado: (2017)

Mutations in spliceosome genes in myelodysplastic neoplasms and their association to ring sideroblasts
por: Huber, Sandra, et al.
Publicado: (2022)

P1508: LUSPATERCEPT REDUCES THE BURDEN OF RED BLOOD CELL TRANSFUSION IN PATIENTS WITH BETA -THALASSEMIA AND COMORBIDITIES: THE EXPERIENCE OF A SINGLE THALASSEMIA AND SICKLE CELL UNIT IN A UNIVERSITY HOSPITAL
por: Delicou, S., et al.
Publicado: (2022)

Population Pharmacokinetics and Exposure–Response of Luspatercept, an Erythroid Maturation Agent, in Anemic Patients With Myelodysplastic Syndromes
por: Chen, Nianhang, et al.
Publicado: (2020)

Luspatercept in Low-Risk Myelodysplastic Syndrome: A Real-World Single Institution Case Series
por: Khan, Shamis, et al.
Publicado: (2022)

The phenotypic spectrum of germline YARS2 variants: from isolated sideroblastic anemia to mitochondrial myopathy, lactic acidosis and sideroblastic anemia 2
por: Riley, Lisa G., et al.
Publicado: (2018)

S273: LONG-TERM ERYTHROID RESPONSE DATA FROM PATIENTS (PTS) WITH NON-TRANSFUSION-DEPENDENT ΒETA-THALASSEMIA (NTDT) RECEIVING LUSPATERCEPT IN THE BEYOND TRIAL
por: Taher, Ali T., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_p2mnunk76jkco888q7a4fei5n5